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Abstract: Targeted therapies have changed the treatment of cancer, giving new hope to many patients
in recent years. The shortcomings of targeted therapies including acquired resistance, limited
susceptible patients, high cost, and high toxicities, have led to the necessity of combining these
therapies with other targeted or chemotherapeutic treatments. Natural products are uniquely capable
of synergizing with targeted and non-targeted anticancer regimens due to their ability to affect
multiple cellular pathways simultaneously. Compounds which provide an additive effect to the often
combined immune therapies and cytotoxic chemotherapies, are exceedingly rare. These compounds
would however provide a strengthening bridge between the two treatment modalities, increasing
their effectiveness and improving patient prognoses. In this study, 7-epi-clusianone was investigated
for its anticancer properties. While previous studies have suggested clusianone and its conformational
isomers, including 7-epi-clusianone, are chemotherapeutic, few cancer types have been demonstrated
to exhibit sensitivity to these compounds and little is known about the mechanism. In this study,
7-epi-clusianone was shown to inhibit the growth of 60 cancer cell types and induce significant
cell death in 25 cancer cell lines, while simultaneously modulating the immune system, inhibiting
angiogenesis, and inhibiting cancer cell invasion, making it a promising lead compound for cancer
drug discovery.
Keywords: cancer; natural compounds; immunomodulation; chemotherapeutics; multitargeting

1. Introduction
In recent years, new hope has been given to patients diagnosed with cancer due to the emergence
of targeted therapeutics [1]. However, due to the limitations of newly discovered targeted therapies,
cancer remains the second leading cause of death in the United States according to the Centers for
Disease Control and Prevention [2,3]. Of the approximately 610,000 deaths caused by cancer in 2018,
over 25% will be due to lung and bronchus cancers, making them the deadliest cancer type in the
United States [4]. The use of targeted therapies has represented a paradigm shift from traditional
chemotherapeutics (often derived from multi-targeting natural products) to molecules and antibodies
affecting specific cellular functions. Within the category of targeted therapies, immune modulating
Molecules 2019, 24, 4415; doi:10.3390/molecules24234415
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therapies have been the source of many novel treatments. Monoclonal antibodies [5], cytokines [6],
dendritic cell therapies [7], chimeric antigen receptor T cells (CAR-T cells) [8], and immune checkpoint
blockade therapies [9] are among the immune modulating treatments that have been approved by the
Food and Drug Administration (FDA) for the treatment of cancer.
Each of these emerging technologies has led to an increase in treatment responses and survival
times, however, major drawbacks have been identified for each. For example, the dendritic cell therapy,
sipuleucel-T, has been shown to be effective in treating early metastatic castration-resistant prostate
cancer, but is extremely costly due to the personalized nature of the treatment [10]. CAR-T cell therapies
similarly function by genetically engineering T cells from a patient to target cancer cells, but come with a
record setting $475,000 price tag, neurotoxicities, and cytokine release syndrome [11,12]. Other immune
regulating treatments, including immune checkpoint blockade therapies such as nivolumab, tend to be
more cost effective but less personalized to each patient [13]. As a result, these treatments are often
used in combination with other therapies. Modulation of the activity of macrophages found within the
tumor microenvironment has also garnered interest as a potential immune regulating cancer therapy,
though the FDA has not currently approved a macrophage-targeted therapy [14].
Targeted therapies used to disrupt the unregulated growth signals of mutated proto-oncogenes
or disrupt angiogenesis have similarly changed the landscape of cancer treatment despite being
accompanied by major drawbacks. Angiogenesis targeting therapies such as bevacizumab and
sorafenib have been used to treat solid and metastatic tumor growth, but similarly suffer from acquired
resistance, likely as a result of plasticity of the tumor microenvironment [15]. The disappointing
performance of targeted therapies has led to a renewed interest in multi-targeting natural products [16].
Natural products have a long history of use as cancer therapies [17], either being used for or
inspiring approximately 60% of cancer treatments used between 1981 and 2006 [18]. These compounds
tend to be safe and of low cost in addition to targeting a number of cellular functions simultaneously.
By targeting multiple cancer related pathways, natural compounds may be able to provide a robust,
widely applicable treatment less susceptible to resistance [19]. Natural products targeting the immune
response in addition to inducing cancer cell death are uniquely positioned to synergize well with current
treatment regimens [20]. Compounds of this type may be able to limit the number of immune therapies
and chemotherapies used in cancer treatment cocktails in addition to increasing their efficacy [21].
The number of compounds with combined chemotherapeutic and immune-modulatory effects is
limited, and many of these compounds are classified as natural products [22]. Notable examples include
astragaloside IV [23,24], curcumin [25], emodin [26,27], and total saponins of panax ginseng [28,29].
These compounds have been demonstrated to induce apoptosis in cancer cells while simultaneously
altering cytokine expression or macrophage polarization. However, the low bioavailability and limited
efficacy of these compounds warrants further drug discovery efforts for multi-targeting compounds.
7-epi-clusianone and its configurational isomers are natural products that have been demonstrated
to feature antimicrobial, anti-allergenic, schistosomicidal, and anti-inflammatory effects [30–33].
Additionally, these compounds have been shown to induce cell death in glioblastoma, as well as lung,
melanoma, breast, prostate, renal, cervical, and tongue cancer [34–37]. Researchers have identified
several potential molecular targets of 7-epi-clusianone, including microtubules, the mitochondrial
membrane, cathepsins, and cyclins [34,36–38]. It is likely that multiple molecules are targeted by
7-epi-clusianone and its isomers due to the so-called “privileged structures” typically possessed by
natural products. Limited in vivo studies have demonstrated the safety of a 7-epiclusianone in vivo in
administrations of up to 300 mg/kg of body weight in female albino mice [30]. Additionally, the chemical
synthesis of 7-epi-clusianone has been explored, allowing for a high availability of the compounds
in the future [39]. As a result, 7-epi-clusianone is a promising lead compound for multi-targeted
cancer treatment. However, screening of 7-epi-clusianone across a wide range of cancers has not yet
been reported. Additionally, only limited studies of the molecular targets of 7-epi-clusianone have
been performed, and the direct interaction of 7-epi-clusianone and its purported targets has yet to be
determined. Finally, the effect of 7-epi-clusianone on the anticancer immune response has not been

ules 2019, 24, x

3

une response has not been explored. To address these knowledge gaps, herein the comb
Molecules 2019, 24, 4415
ancer and immune
modulatory effects of 7-epi-clusianone are examined. 3 of 19

sults

explored. To address these knowledge gaps, herein the combined anticancer and immune modulatory
effects of 7-epi-clusianone are examined.
2. Results

-epi-clusianone Inhibits Cell Growth and Induces Cell Death in a Wide Spectrum of Cancers
2.1. 7-epi-clusianone Inhibits Cell Growth and Induces Cell Death in a Wide Spectrum of Cancers
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Figure 1. The structure of the polycyclic polyprenylated acylphloroglucinol, 7-epi-clusianone.

Figure 1. The structure of the polycyclic polyprenylated acylphloroglucinol, 7-epi-clusianone.
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bronchus cancers are projected to be responsible for over one quarter of all cancer-related deaths in
the United States in 2018, and therefore possess a higher potential for clinical impact compared to
other tissue types in the NCIH460 panel, the effect of 7-epi-clusianone on small cell lung cancer was
investigated further. The non-small cell lung cancer cell line, NCIH460, was the most sensitive lung
cancer cell line to 7-epi-clusianone when considering induced cell death (LD50) and was chosen for
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investigation as a result. The GI50, TGI, and LD50 concentrations of the NCIH460 cell4 line
were 2.6 µM, 6.2 µM, and 35 µM, respectively (Figure 2).

Figure 2. Percent growth of NCIH460 non-small cell lung cancer cells after 48 h of treatment with
7-epi-clusianone in the NCI-60 panel. The NCI-60 panel is a sulforhodamine B based screening method
of 60 immortalized cancer cell lines. The GI50, TGI, and LD50 concentrations of 7-epi-clusianone for the
NCIH460 cells were determined to be 2.6 µM, 6.2 µM, and 35 µM, respectively.

2.2. 7-epi-clusianone Induces G1 Arrest Followed by Apoptosis in NCIH460 Small Cell Lung Cancer Cells
In order to gain insight into the mechanism of action of 7-epi-clusianone on NCIH460 small cell
lung cancer cells, the cell cycle of the NCIH460 cells over 48 h under exposure to 7-epi-clusianone
was analyzed by quantifying the amount of PI bound to DNA within the cells using flow cytometry
(Figure 3A–C). When the NCIH460 cells were treated with 35 µM of the compound the number of
cells in the G1 phase of the cell cycle increased at 12 and 24 h of incubation when compared to the
vehicle control. Additionally, a depletion of cells in the S and G2/M phases of the cell cycle occurred
after 24 h when compared to the control and persisted after 48 h. The percent of cells in the S phase
decreased at a rate faster than the percent of cells in the G2/M phase decreased when exposed to
7-epi-clusianone, suggesting that cells were progressing from the S phase to G2/M phase, but they were
unable to progress from the G1 phase to S phase when exposed to 7-epi-clusianone. At the 48-h time
point, the percentage of cells in the G1 phase decreased when compared to the percent of cells in the
G1 phase at 24 h when exposed to 7-epi-clusianone. As the percent of cells in the S and G2/M phases
continued to decrease over this same time period, this decrease in G1 phase cells can be explained by
the increase in sub G1 cells seen from 24 h to 48 h of incubation with 7-epi-clusianone. These sub G1
cells are hypothesized to be dead cells with cleaved DNA.
Annexin V/PI expression for the NCIH460 cells after 48 h of incubation with 7.6 µM, 15 µM,
35 µM, and 61 µM 7-epi-clusianone was determined to evaluate whether the cells observed in the
sub-G1 phase had undergone apoptosis (Figure 4). As the concentration was increased the number
of live cells decreased, confirming the dose dependent cytotoxicity of 7-epi-clusianone on NCIH460
cells. In each of the 7-epi-clusianone-treated groups, the number of apoptotic and necrotic cells
increased when compared to the vehicle control (Figure 4A). The number of apoptotic, Annexin V
positive, cells increased as the concentration of 7-epi-clusianone was increased. Additionally, at lower
concentrations, a population of PI positive and Annexin V low cells was observed (Figure 4B,C).
This suggests that at lower concentrations, a population of NCIH460 cells were just beginning to
permeabilize and therefore were in an earlier stage of apoptosis after 48 h than were cells treated with
a higher dose of 7-epi-clusianone (Figure 4D–F).

unable to progress from the G1 phase to S phase when exposed to 7-epi-clusianone. At the 48-h time
point, the percentage of cells in the G1 phase decreased when compared to the percent of cells in the
G1 phase at 24 h when exposed to 7-epi-clusianone. As the percent of cells in the S and G2/M phases
continued to decrease over this same time period, this decrease in G1 phase cells can be explained by
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We also determined the caspase activity of the NCIH460 cells to support the hypothesis
that apoptosis occurs after exposure to 7-epi-clusianone. The quantity of inactive/full length and
active/cleaved forms of caspases 7, 8, 3, and 9 present with the NCIH460 cells was determined using
western blotting (Figure 5). After 12 and 24 h of exposure to 7-epi-clusianone, the full length form
of caspases 7 and 8 decreased as the concentration was increased, but the cleaved forms of these
caspases were not detected. No trend was apparent from the quantity of caspase 3 detected at either
time point. However, the ratio of cleaved caspase 9 to full length caspase 9 increased dramatically for
NCIH460 cells treated with 7.6 µM or 15 µM of 7-epi-clusianone for 12 or 24 h. Additionally, a doseand time-dependent increase in the ratio of cleaved Poly (ADP-ribose) polymerase (PARP) to full
length PARP occurred under incubation with 7-epi-clusianone. The cleavage of caspase 9 and PARP
further supports that 7-epi-clusianone induces apoptosis in NCIH460 lung cancer.

each of the 7-epi-clusianone-treated groups, the number of apoptotic and necrotic cells increased
when compared to the vehicle control (Figure 4A). The number of apoptotic, Annexin V positive,
cells increased as the concentration of 7-epi-clusianone was increased. Additionally, at lower
concentrations, a population of PI positive and Annexin V low cells was observed (Figure 4B and
Figure 4C). This suggests that at lower concentrations, a population of NCIH460 cells were just
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beginning to permeabilize and therefore were in an earlier stage of apoptosis after 48 h than were
cells treated with a higher dose of 7-epi-clusianone (Figure 4D–F).
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We also determined the caspase activity of the NCIH460 cells to support the hypothesis that
apoptosis occurs after exposure to 7-epi-clusianone. The quantity of inactive/full length and
active/cleaved forms of caspases 7, 8, 3, and 9 present with the NCIH460 cells was determined using
western blotting (Figure 5). After 12 and 24 h of exposure to 7-epi-clusianone, the full length form of
caspases 7 and 8 decreased as the concentration was increased, but the cleaved forms of these
caspases were not detected. No trend was apparent from the quantity of caspase 3 detected at either
time point. However, the ratio of cleaved caspase 9 to full length caspase 9 increased dramatically for
NCIH460 cells treated with 7.6 µM or 15 µM of 7-epi-clusianone for 12 or 24 h. Additionally, a doseand time-dependent increase in the ratio of cleaved Poly (ADP-ribose) polymerase (PARP) to full
length PARP occurred under incubation with 7-epi-clusianone. The cleavage of caspase 9 and PARP
further supports that 7-epi-clusianone induces apoptosis in NCIH460 lung cancer.

Figure 5. Expression of apoptosis-related proteins in NCIH460 cells after treatment with 7-epi-clusianone
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2.3. 7-epi-clusianone Inhibits Angiogenesis and Cell Migration of NCIH460 Cells
After determining 7-epi-clusianone’s ability to induce cell death at high concentrations, the
ability of 7-epi-clusianone to inhibit cell migration of NCIH460 cells at low concentrations was
assessed. A uniform cell gap was formed using cell culture insert, and the cells were allowed to grow
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2.3. 7-epi-clusianone Inhibits Angiogenesis and Cell Migration of NCIH460 Cells
After determining 7-epi-clusianone’s ability to induce cell death at high concentrations, the ability
of 7-epi-clusianone to inhibit cell migration of NCIH460 cells at low concentrations was assessed.
A uniform cell gap was formed using cell culture insert, and the cells were allowed to grow for up
to 24 h exposed to either a vehicle control or 7-epi-clusianone (Figure 6A,B). After 24 h, the cell-free
gap had almost completely closed for cells treated with the vehicle control. In contrast, after 24 h
of incubation with 7-epi-clusianone the percent invasion of NCIH460 cells was significantly lower
compared to the control for each concentration used, including 200 nM, a concentration 10-times lower
than the GI50 concentration. At each time point considered (6, 12, and 24 h), a dose dependent decrease
in invasion was observed. Also, the toxicity effects of 7-epi-clusianone was evaluated by tracking the
NCIH460 viability at 24 h using MTS assay. No significant difference (p ≤ 0.05) in cell viability was
observed when we compared the treated cells with blank control group (Figure 6C). This indicates that
the reduction in cell invasion in the presence of higher compound concentrations is not affected by
Molecules 2019, 24, x
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cell viability.
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Similarly, the ability of 7-epi-clusianone to inhibit angiogenesis was indirectly assessed. Human
Similarly, the ability of 7-epi-clusianone to inhibit angiogenesis was indirectly assessed. Human
umbilical vascular endothelial cells (HUVEC) endothelial cells were incubated with or without
umbilical vascular endothelial cells (HUVEC) endothelial
cells were incubated with or without 7-epiTM basement
7-epi-clusianone on a growth factor reduced BD Matrigel
matrix. Tube formation between
clusianone on a growth factor reduced BD MatrigelTM basement matrix. Tube formation between the
the endothelial cells was assessed after 8 h (Figure 7A). A dose dependent reduction of tube formation
endothelial cells was assessed after 8 h (Figure 7A). A dose dependent reduction of tube formation
was observed when the cells were exposed to 7-epi-clusianone at concentrations between 0.2 and 20 µM
was observed when the cells were exposed to 7-epi-clusianone at concentrations between 0.2 and 20
(Figure 7B). The reduction of tube formation became significant (p ≤ 0.05) at 20 µM 7-epi-clusianone.
µM (Figure 7B). The reduction of tube formation became significant (p ≤ 0.05) at 20 µM 7-epiAn MTS viability assay of HUVEC endothelial cells in response to 7-epi-clusianone for 8 h revealed
clusianone. An MTS viability assay of HUVEC endothelial cells in response to 7-epi-clusianone for 8
h revealed that the compound was not toxic at this time point (Figure 7C). No significant difference
in viability was observed in these cells even at the highest concentration of 20 µM 7-epi-clusianone.
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2.4. 7-epi-clusianone Directly Targets Tubulin Polymerization, JAK3, and ALK (C1156Y)
2.4. 7-epi-clusianone Directly Targets Tubulin Polymerization, JAK3, and ALK (C1156Y)
While the cytotoxic effect of 7-epi-clusianone on a number of cell lines has been previously reported,
While the cytotoxic effect of 7-epi-clusianone on a number of cell lines has been previously
the direct effect of 7-epi-clusianone on its purported molecular targets has yet to be determined [34–37].
reported, the direct effect of 7-epi-clusianone on its purported molecular targets has yet to be
Due to the identification of microtubules as a potential target of clusianone in other lung cancer
determined [34–37]. Due to the identification of microtubules as a potential target of clusianone in
cell lines [37], the effect of 7-epi-clusianone on tubulin polymerization was investigated using the
other lung cancer cell lines [37], the effect of 7-epi-clusianone on tubulin polymerization was
cytoskeleton tubulin polymerization assay (Figure 8). While the nucleation time, i.e., the time required
investigated using the cytoskeleton tubulin polymerization assay (Figure 8). While the nucleation
for tubulin to begin polymerizing, was not affected by the presence of 7-epi-clusianone, the rate at which
time, i.e., the time required for tubulin to begin polymerizing, was not affected by the presence of 7the tubulin polymerized was significantly increased by 100 and 200 µM of 7-epi-clusianone (Figure 8A).
epi-clusianone, the rate at which the tubulin polymerized was significantly increased by 100 and 200
The rate at which the tubulin polymerized is best represented by the Vmax value, which corresponds
µM of 7-epi-clusianone (Figure 8A). The rate at which the tubulin polymerized is best represented by
to the highest ratio of increase in the absorbance at 340 nm to time for each treatment group. We
the Vmax value, which corresponds to the highest ratio of increase in the absorbance at 340 nm to
observed a dose dependent increase in Vmax, consistent with the increase in Vmax observed in the
time for each treatment group. We observed a dose dependent increase in Vmax, consistent with the
presence of the known microtubule stabilizing agent, paclitaxel [40] (Figure 8B).
increase in Vmax observed in the presence of the known microtubule stabilizing agent, paclitaxel [40]
To determine the ability of 7-epi-clusianone to target tyrosine receptor kinases, a common target of
(Figure 8B).
cancer therapeutics, the compound was screened using the DiscoverX scanTK kinase panel. This panel
To determine the ability of 7-epi-clusianone to target tyrosine receptor kinases, a common target
determines the ability of a compound to inhibit the activity of 135 different tyrosine kinases. A reduction
of cancer therapeutics, the compound was screened using the DiscoverX scanTK kinase panel. This
of kinase activity to 30% or below is considered significant in this one dose screen. At a concentration
panel determines the ability of a compound to inhibit the activity of 135 different tyrosine kinases. A
of 20 µM, 7-epi-clusianone significantly inhibited two kinases, anaplastic lymphoma kinase C1156Y
reduction of kinase activity to 30% or below is considered significant in this one dose screen. At a
(ALK C1156Y) and janus kinase 3 (JAK3). The activity of ALK (C1156Y) and JAK3 were inhibited by
concentration of 20 µM, 7-epi-clusianone significantly inhibited two kinases, anaplastic lymphoma
70% and 75% respectively. ALK (C1156Y) is a mutation of the ALK tyrosine kinase, which has been
kinase C1156Y (ALK C1156Y) and janus kinase 3 (JAK3). The activity of ALK (C1156Y) and JAK3
associated with acquired resistance to the targeted ALK inhibitor, crizotinab, used for the treatment of
were inhibited by 70% and 75% respectively. ALK (C1156Y) is a mutation of the ALK tyrosine kinase,
small cell lung cancer [41]. JAK3 is a kinase that plays a role in the immune response of several types
which has been associated with acquired resistance to the targeted ALK inhibitor, crizotinab, used
of cells [42]. Kinase assay report is found in the supplementary information Table S2.
for the treatment of small cell lung cancer [41]. JAK3 is a kinase that plays a role in the immune
response of several types of cells [42]. Kinase assay report is found in the supplementary information
Table S2.
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2.5. 7-epi-clusianone Increases the Expression of Pro-Inflammatory Cytokines in THP-1 Macrophages
2.5. 7-epi-clusianone Increases the Expression of Pro-Inflammatory Cytokines in THP-1 Macrophages
In order to determine the effect of 7-epi-clusianone on the immune response, cytokine concentration
In order to determine the effect of 7-epi-clusianone on the immune response, cytokine
was assessed on M0 macrophages. A shift in M0, naïve macrophages, to M1 polarized, pro-inflammatory
concentration was assessed on M0 macrophages. A shift in M0, naïve macrophages, to M1 polarized,
and anticancer macrophages, is denoted by an increase in inflammatory cytokines, including TNFα
pro-inflammatory and anticancer macrophages, is denoted by an increase in inflammatory cytokines,
and IL-6 among others. We assessed the expression of these cytokines by THP-1 macrophages after 72 h
including TNFα and IL-6 among others. We assessed the expression of these cytokines by THP-1
of incubation with 7-epi-clusianone (Figure 9). In addition, using rt-PCR, we examined the phenotypic
macrophages after 72 h of incubation with 7-epi-clusianone (Figure 9). In addition, using rt-PCR, we
markers of M1 macrophages (TNFα and IL-6) as a positive control. Both the gene expression of the
examined the phenotypic markers of M1 macrophages (TNFα and IL-6) as a positive control. Both
cytokines and the concentration of the cytokine excreted into the cell culture media were determined
the gene expression of the cytokines and the concentration of the cytokine excreted into the cell
by rt-PCR and ELISA, respectively. To ensure that the concentrations of 7-epi-clusianone tested on
culture media were determined by rt-PCR and ELISA, respectively. To ensure that the concentrations
macrophages were adequate, the viability and invasion capability of the macrophages under exposure to
of 7-epi-clusianone tested on macrophages were adequate, the viability and invasion capability of the
7-epi-clusianone was tested and no significant changes were observed (Figure S4). The gene expression
macrophages under exposure to 7-epi-clusianone was tested and no significant changes were
of both TNFα and IL-6 increased as the concentration of 7-epi-clusianone was increased (Figure 9A,B,
observed (Figure 4S). The gene expression of both TNFα and IL-6 increased as the concentration of
respectively). At 20 µM of 7-epi-clusianone, the gene expression of both cytokines had increased 60–70
7-epi-clusianone was increased (Figure 9A,B, respectively). At 20 µM of 7-epi-clusianone, the gene
fold over the expression of the control, untreated macrophages. While a dose dependent increase in the
expression of both cytokines had increased 60–70 fold over the expression of the control, untreated
presence of each cytokine in the media of the cells also occurred, this increase was not significant when
macrophages. While a dose dependent increase in the presence of each cytokine in the media of the
compared to the control (Figure 9C,D). As mentioned above, TNFα and IL-6 are the main markers
cells also occurred, this increase was not significant when compared to the control (Figure 9C,D). As
of M1 macrophage phenotype. These markers were found elevated in M1 macrophages as well as
mentioned above, TNFα and IL-6 are the main markers of M1 macrophage phenotype. These markers
M0 macrophages that were treated with 7-epi-clusianone (Figure 9A,B). The data showed that the
were found elevated in M1 macrophages as well as M0 macrophages that were treated with 7-epiexpression of inflammatory genes was augmented when M0 macrophages were exposed to 0.2 µM or
clusianone (Figure 9A,B). The data showed that the expression of inflammatory genes was
higher concentrations. Strikingly, the inflammatory response reaches to the level of M1 macrophages
augmented when M0 macrophages were exposed to 0.2 µM or higher concentrations. Strikingly, the
when we exposed M0 macrophages to 20 µM of 7-epi-clusianone. These results indicate the potential
inflammatory response reaches to the level of M1 macrophages when we exposed M0 macrophages
of 7-epi-clusianone to polarize M0 macrophages to anticancer M1 macrophages.
to 20 µM of 7-epi-clusianone. These results indicate the potential of 7-epi-clusianone to polarize M0
macrophages to anticancer M1 macrophages.
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Natural products have been instrumental in the treatment of cancer and are currently garnering
renewed
interest as lead compounds for cancer therapies and complementary treatments due to the
3. Discussion
shortcomings of targeted therapeutics. Compounds which simultaneously affect immune regulation of
Natural products have been instrumental in the treatment of cancer and are currently garnering
cancer and induce cancer cell death may provide a uniquely well suited complementary treatment
renewed interest as lead compounds for cancer therapies and complementary treatments due to the
to current targeted therapy and chemotherapy regimens. 7-epi-clusianone and its configurational
shortcomings of targeted therapeutics. Compounds which simultaneously affect immune regulation
isomers, are natural products that have been shown to exhibit a wide array of biological effects.
of cancer and induce cancer cell death may provide a uniquely well suited complementary treatment
The anticancer effects of 7-epi-clusianone have been previously investigated in a limited number of
to current targeted therapy and chemotherapy regimens. 7-epi-clusianone and its configurational
cancer cell lines [34–37], but the mechanism of action and the molecular targets of the compound have
isomers, are natural products that have been shown to exhibit a wide array of biological effects. The
not been fully investigated, nor has its ability to modulate the immune response to cancer.
anticancer effects of 7-epi-clusianone have been previously investigated in a limited number of cancer
In this study, 7-epi-clusianone was demonstrated to inhibit the growth of cancer cells across 9
cell lines [34–37], but the mechanism of action and the molecular targets of the compound have not
tissue types and 60 individual cancer cell lines. A growth inhibitory effect was observed for each cell
been fully investigated, nor has its ability to modulate the immune response to cancer.
line, but an LD50 less than the highest concentration tested was only observed in 25 of the 60 cell lines
In this study, 7-epi-clusianone was demonstrated to inhibit the growth of cancer cells across 9
tested. These 25 cell lines were composed of cell lines from each tissue type tested excluding leukemia.
tissue types and 60 individual cancer cell lines. A growth inhibitory effect was observed for each cell
In combination, these effects suggest that 7-epi-clusianone could be used to slow the progression of
line, but an LD50 less than the highest concentration tested was only observed in 25 of the 60 cell lines
many variations of cancer, but it will not be cytotoxic to all types of cells. As 7-epi-clusianone is likely
tested. These 25 cell lines were composed of cell lines from each tissue type tested excluding
to be safe in vivo at relatively high concentrations [30] and the compound is selective in inducing cell
leukemia. In combination, these effects suggest that 7-epi-clusianone could be used to slow the
death, has the potential to be safely used for the treatment of a diverse group of cancers. In particular,
progression of many variations of cancer, but it will not be cytotoxic to all types of cells. As 7-epirenal cancer, melanoma, central nervous system tumors, colon cancer, and non-small cell lung cancer
clusianone is likely to be safe in vivo at relatively high concentrations [30] and the compound is
appear to be sensitive to the cytotoxic effects of 7-epi-clusianone. It is unclear what factors determine the
selective in inducing cell death, has the potential to be safely used for the treatment of a diverse group
of cancers. In particular, renal cancer, melanoma, central nervous system tumors, colon cancer, and
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sensitivity of each cancer cell line to 7-epi-clusianone, and further study will be required to determine
how to best predict sensitivity within a particular cancer tissue. 7-epi-clusianone’s anticancer effects
have the biggest potential for clinical impact due to the high rate of lung cancer related death in the
United States. 7-epi-clusianone has the ability to induce cell death in non-small cell lung cancer cell
lines and inhibit an ALK tyrosine kinase mutation responsible for acquired resistance to treatment.
In order to further investigate the anticancer effect of 7-epi-clusianone on non-small cell lung cancer,
additional experiments were performed on a lung cancer cell line which had exhibited sensitivity to
the compound. The non-small cell lung cancer cell line that had exhibited the greatest sensitivity to
7-epi-clusianone was NCIH460. Cell cycle analysis revealed that the cell death was preceded by G1
phase arrest, and a subsequent reduction of S phase and G2/M phase cells. A similar G1 phase arrest
has been observed after treatment of A549 lung cancer cells with 7-epi-clusianone suggesting a similar
mechanisms of action for inducing cytotoxicity across lung cancer cell types [37].
The cell death induced in NCIH460 cells by 7-epi-clusianone is hypothesized to proceed through an
apoptotic mechanism. As the concentration increased, more annexin V positive cells were observed via
flow cytometry. It should be noted that both cells undergoing necrosis and apoptosis may be positive
for both PI and Annexin V at late stages of cell death and therefore the Annexin V/PI flow cytometry
results in Figure 5 do not conclusively show apoptosis occurred. However, the population of Annexin
V positive cells with low PI staining observed with treatment of 7.6 and 15 µM of 7-epi-clusianone
suggests the presence of cells which are leaving early apoptosis (when the intact cell membrane
prevents PI staining) and entering late apoptosis (when the cell membrane begins to permeabilize).
This population appears to dissipate at higher concentrations of 7-epi-clusianone as the cells enter
apoptosis more rapidly.
The apoptosis hypothesis was supported by the cleavage of caspase 9 and PARP, which participate
in the caspase cascade leading to cell death after mitochondrial depolarization has occurred [43,44].
Cleavage of caspase 9 and PARP in NCIH460 was evidenced by the decrease in the abundance of full
length caspase 9 and PARP and the increase in the abundance of cleaved caspase 9 and PARP as the
concentration of 7-epi-clusianone was increased. A decrease in full length caspase 7 and caspase 8
expression upon treatment of NCIH460 cells with 7-epi-clusianone was also observed. The decrease
in full length caspase 7 and 8 was further evidence that the caspase cascade leading to apoptotic cell
death had been activated, however the lack of cleaved caspase 7 and 8 observed makes this finding
inconclusive. Additionally, whether caspase 9 was activated through the receptor mediated apoptosis
pathway or the intrinsic apoptosis pathway was not possible to determine due to the lack of cleaved
caspase 7 or 8 [44]. The absence of cleaved caspase 7 or 8 in this study does not, however, rule out the
possibility of receptor mediated or intrinsic apoptosis as the cleaved proteins may have been present at
earlier incubation time points before being digested by the cell.
In addition to inducing dose dependent apoptosis in non-small cell lung cancer, 7-epi-clusianone
also inhibited the invasion of NCIH460. Significant invasion inhibition was observed at a concentration
as low as 200 nM. Further, 7-epi-clusianone was shown to significantly reduce the tube formation
between HUVEC endothelial cells at a concentration of 20 µM. Tube formation is a critical step in
the process of angiogenesis which is utilized by the wound healing process as well as by cancers
to feed tumor growth [45–47]. By inhibiting angiogenesis and tumor cell invasion, 7-epi-clusianone
may act to inhibit continued tumor growth and metastasis of non-small cell lung cancer into healthy
tissue. These effects were seen in concentrations less than the concentrations required to induce cell
death, suggesting 7-epi-clusianone directly inhibits molecular targets associated with angiogenesis and
invasion which were outside the scope of this study.
Mechanistic studies were however performed to elucidate the mechanism by which
7-epi-clusianone induces cell death in non-small cell lung cancer. For the first time, the direct
effect of 7-epi-clusianone on cancer proliferation targets including microtubules and ALK (C1156Y)
was determined. While 7-epi-clusianone has been previously suggested to impact microtubule
structure [37], the mechanism of this effect was unclear. This study demonstrated that 7-epi-clusianone
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acts by stabilizing and increasing the rate of polymerization of tubulin directly. This mechanism of action
is one shared by chemotherapy agents, such as paclitaxel, though the concentration of 7-epi-clusianone
required to impact the polymerization of tubulin was high compared to the concentration necessary
to induce growth inhibition or cell death on NCIH460 cells. As a result, it is likely that additional
molecular targets are influenced by 7-epi-clusianone in order to impart its cytotoxic effects. We further
determined that 7-epi-clusianone directly inhibits the function of two tyrosine kinases, ALK (C1156Y)
and JAK3. While these molecular targets are not largely present within NCIH460 lung cancer, and thus
are not likely to be involved with a mechanism of cell death, they do suggest 7-epi-clusianone may
target non-small cell lung cancer cells with acquired resistance to kinase inhibitors.
Due to the increasing role of immune targeted therapies in lung cancer, the ability of 7-epi-clusianone
to modulate the immune system within the tumor microenvironment was also investigated [48].
Macrophages are immune cells that play a role in T-cell activation in addition to engulfing pathogens
and dead cells. Within the tumor microenvironment, tumor associated macrophages (TAMs) can
be formed, which resemble macrophages polarized to an M2, anti-inflammatory state and aid in
tumor growth and evasion from the immune system [49]. While some studies have suggested
eliminating TAMs as a therapeutic strategy, others have hypothesized that polarizing macrophages
to the M1 state within the tumor microenvironment will not only eliminate the tumor-supportive
functions of TAMs but will also activate the immune system against the tumor [50]. In this study,
7-epi-clusianone was shown to increase the gene expression of TNFα and IL-6 within THP-1 derived
macrophages, suggesting that cells polarize to an anticancer phase, pro-inflammatory M1 macrophages.
This regulation of macrophages suggests that 7-epi-clusianone might be a useful complementary
treatment when combined with current first-in-line immune therapies. This is especially true in the
case of CAR-T cell therapy, in which macrophage dysfunction is the source of some of the most serious
side effects [12].
Future studies will be required to determine the effectiveness of 7-epi-clusianone as a cancer therapy.
More mechanistic studies should be performed to elucidate the primary targets for 7-epi-clusianone’s
cytotoxic and immune regulatory properties. Of particular interest to future studies should be the
effect of 7-epi-clusianone on non-small cell lung cancer due the high mortality rates of this malignancy
and the compound’s ability to induce apoptosis and inhibit invasion of non-small cell lung cancer cell
lines. With this information, the groundwork will be laid to perform in vivo determinations of the
efficacy of 7-epi-clusianone in inducing cancer cell death and regulating the immune response.
7-epi-clusianone is a promising lead compound for anticancer therapies due to its combined
apoptotic, anti-angiogenesis, anti-invasion, and immune-regulating properties. The natural compound
was shown to have three direct molecular targets in this study, with more targets likely undiscovered.
The multi-targeting nature of 7-epi-clusianone stands to provide a complementary treatment to emerging
targeted oncology therapeutics, which suffer from limited efficacy when used alone as well as toxicities
and acquired resistance. Additionally, 7-epi-clusianone may combine growth inhibitory and cytotoxic
effects on cancer cells with a modulation of the tumor microenvironment to oppose the formation
and spread of cancer when used alone. In summary, 7-epi-clusianone may provide a robust and
multipronged treatment for cancer, especially non-small cell lung cancer.
4. Materials and Methods
4.1. 7-epi-clusianone Source and Identification
The polycyclic polyprenylated acylphloroglucinol, 7-epi-clusianone, was isolated from the aerial
parts of Hypericum scabrum. Air-dried, powdered aerial parts of Hypericum scabrum (5.0 kg) were
extracted with n-hexane (4 × 20 L) by maceration at room temperature. The extract was concentrated
in vacuum to afford dark gummy residue (150 g). The residue was separated on a silica gel column
(230−400 mesh, 6 × 75 cm, 800 g) with a gradient of n-hexane-EtOAc (100:0 to 0:100) as eluent, followed by
increasing concentrations of MeOH (up to 50%) in EtOAc. After screening by TLC, fractions with similar
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compositions were pooled, to yield 15 combined fractions. From fraction eluted with n-hexane–EtOAc
(95:5) a yellow crude solid was obtained, which was triturated with MeOH to give 7-epi-clusianon as
white powder (100 mg). The isolated compound was stored in a sealed vial in the dark, at 4 ◦ C, until
used. The structure was elucidated by a combination of 1D and 2D nuclear magnetic resonance (NMR,
Bruker, Billerica, MA, USA) and time of flight mass spectrometry, as well as comparing with the data in
literature [51]. For NMR analysis, 7-epi-clusianone was dissolved in dimethyl sulfoxide (DMSO) and
analyzed using a Bruker Avance III-HD 400 MHz. 1 H-NMR, 13 C-NMR, H-H correlation spectroscopy
(COSY), heteronuclear single quantum coherence (HSQC), and heteronuclear multiple bond correlation
(HMBC) spectrums were generated. For mass spectrophotometry analysis, 7-epi-clusianone was
dissolved in methanol and analyzed using liquid chromatography-mass spectrometry (LC-MS) on a
Thermo Orbitrap Velos Pro. NMR and mass spectrometry (MS) data can be found in Figures S1 and S2.
For all cell culture experiments, 7-epi-clusianone was diluted in DMSO at a concentration of 20 mM
before being diluted into the cell culture media specified for each cell line.
4.2. Cell Lines and Reagents
The non-small-cell lung cancer cell line, NCIH460, was purchased from the Development
Therapeutics Program, Division of Cancer Treatment and Diagnosis tumor repository. NCIH460 cells
were maintained in RPMI-1640 media (Corning, Corning, New York) supplemented with 10% Fetal
Bovine Essence (FBS; VWR, Radnor, PA, USA) and 2 mM L-glutamine (Sigma Aldrich, St. Louis, MO,
USA). THP-1 human monocytic cells were obtained from American Type Culture Collection (ATCC,
Manassas, WV, USA). THP-1 cells were maintained in RPMI-1640 media supplemented with 10% FBS
and 0.05 mM 2-mercaptoethanol (Sigma Aldrich, St. Louis, MO, USA). Human umbilical vascular
endothelial cells (HUVEC) were purchase from Lonza Inc. HUVEC were cultured in endothelial cell
basal media 2 (EBM-2, Lonza Inc., Basel, Switzerland) supplemented with endothelial growth medium
bulletkit (EGM-2; Lonza, Inc., Basel, Switzerland).
THP-1 cells were differentiated into THP-1 M0 macrophages by culturing the cells with 100 ng/mL
of 12-myristate 13-acetate (PMA; Sigma Aldrich, St. Louis, MO, USA) for 24 h. After differentiation,
the cells were washed three times with serum free RPMI-1640 medium (Gibco, Dublin, Ireland)
to remove non-differentiated cells. To activate, M0 macrophages were treated with 100 ng/mL of
lipopolysaccharide (LPS, Sigma Aldrich, St. Louis, MO, USA and 20 ng/mL of interferon gamma
(IFN-γ, Peprotech, Rock Hills, NJ, USA) for 24 h. Polarized M0 macrophages were used as a positive
control for comparison to groups that were treated with the compound.
4.3. NCI-60 Cell Line Screening
Cytotoxicity screening was performed using the National Institute of Health’s (NIH) National
Cancer Institute-60 (NCI-60) screening program [52]. This panel utilized a Sulforhodamine B assay to
quantify the total cellular protein present after 48 h of treatment with a 7-epi-clusianone. The panel
screened 60 unique cancer cell lines. After sufficient activity was observed using one dose of
7-epi-clusianone (20 µM), the screening was repeated using a five-point dilution. For each of the cell
lines, the concentration of compound required to reduce the growth of cells to 50% that of the vehicle
control (GI50), the concentration required to inhibit the growth of any amount of cells (TGI), and
the concentration required to induce cell death of 50% of the seeded cells (LD50) was determined.
A thorough description of the panel and its development is given by Shoemaker [53].
4.4. Cytotoxicity Assay (MTS)Assay
In order to determine cell viability, HUVECs and NCIH460 were cultured in their growth media
to reach 80% confluency. HUVECs and NCIH460 were seeded at a density of 5 × 103 and 4 × 103
cell per 96 well plates, respectively. For all cell types, 100 µL of cell culture media was used. The
cells were then incubated for 24 h at 37 ◦ C and 5% CO2 to allow for cell attachment. The culture
media was aspirated and media supplemented with the different concentrations of 7-epi-clusianone
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(0.2, 2, and 20 µM) was replaced. The compound was first dissolved at a concentration of 10 mg/mL
in DMSO and subsequently diluted in culture media. Following 8 and 24 h incubation for HUVECs
and NCIH460, media containing 20% MTS solution was replaced with growth media and incubated
for 2 h. The absorbance of each well at 490 nm was measured using a Spectramax 190 spectrometer
(Molecular Devices Corporation, Sunnyvale, CA, USA).
4.5. In Vitro Invasion Assay
Cell migration of NCIH460 (60 × 104 cells/well) and THP-1 (100,000 cells/well) cells was assessed by
making a cell-free gap with a Culture-Insert (IbiTreat, Martinsried, Germany) following manufacturer’s
instructions. Twenty-four hours later, the inserts were removed, and cell debris was washed with
phosphate buffered saline (PBS). The samples were supplemented with different concentrations of
7-epi-clusianone in cell culture media and incubated at 37 ◦ C and 5% CO2 for 24 h. Images were taken at
different time intervals using a phase contrast Nikon Eclipse Ti-E inverted microscope. Quantification of
the percent invasion was performed by measuring the gap distance using the following formula,
invasion % =

( W0 − Wn )
∗ 100%
W0

(1)

where Wn is the average of three gap width measurements at 6, 12, or 24 h, and W 0 is the initial
width of the cell-free gap. The media was removed, and the cells were stained with cell stain solution
(Cell Biolabs, Inc. San Diego, CA, USA). Images were taken using a phase contrast inverted microscope
(Invitrogen EVOS FL Auto Cell Imaging).
4.6. Tube Formation Assay
Growth factor reduced BD MatrigelTM (Corning, Corning, NY, USA) was thawed on ice at 4 ◦ C
overnight. Next, 50 µL of MatrigelTM was added to each well of a pre-chilled 96-well plate and
incubated at 37 ◦ C and 5% CO2 for 30 min until the MatrigelTM had formed a gel. A suspension of
20,000 HUVEC in 100 µL of cell culture media dosed with 7-epi-clusianone was added to each well.
The vehicle control consisted of only HUVEC cells and growth media. At the end of the 8-h time
point, the cells were stained with cell stain solution as outlined in the in vitro invasion assay protocol.
The junctions, or tubes, connecting the endothelial cells were photographed using an Invitrogen EVOS
FL Auto at 4× magnification and counted manually.
4.7. Cell Cycle Analysis
The effect of 7-epi-clusianone on the cell cycle of NCIH460 cells was determined using flow
cytometry. The cells were seeded (2500 cells/cm2 ) allowed to attach and treated with 7-epi-clusianone.
At 6, 12, 24, and 48 h of treatment, the drugged media was collected, and the cells were trypsinized,
and centrifuged. The resulting pellet was suspended in 1 mL of ice-cold PBS, which was then added
dropwise to 3 mL of ice-cold 70% ethanol in deionized water. The suspension was kept at 4 ◦ C for at least
24 h to allow the cells to fix. Once all time points had been collected, the cells were again centrifuged
and the resulting pellets were suspended in FxCycle PI/RNase Staining Solution (Invitrogen, Carlsbad,
CA, USA) for 15 min, then analyzed using a BD LSR II flow cytometer. Propidium iodide (PI; Life
Technologies, Carlsbad, CA, USA) expression was used to quantify the percentage of cells in the
sub-G1, G0/G1, S, and G2/M phases.
4.8. Annexin V/PI Apoptosis Assay
The ability of the 7-epi-clusianone to induce apoptosis in NCIH460 cells was determined using the
FITC Annexin V/ Dead Cell Apoptosis Kit (Invitrogen, Carlsbad, CA, USA). The cells were seeded
(2000 cells/cm2 ) allowed to attach and treated with 7-epi-clusianone. After 48 h of incubation, the media
was collected, and the cells were trypsinized and centrifuged. The supernatant was discarded, and the
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pellet was washed with ice cold PBS, centrifuged, and resuspended in Annexin V buffer at 1,000,000
cells/mL. Next, 100 µL of the cell suspensions were added to flow cytometry tubes, and 5 µL of Annexin
V/FITC antibody and 1 µL of PI working solution were added to each sample. The samples were
incubated for 15 min at room temperature and analyzed using a BD LSR II flow cytometer.
4.9. Western Blotting
The effect of 7-epi-clusianone on apoptosis related proteins in NCIH460 cells was assessed using
western blotting. The cells were seeded at a density of 60,000 cell/cm2 and allowed to attach for
24 h. Then, the media was replaced with media supplemented with either a vehicle control or the
designated concentration of 7-epi-clusianone and incubated for 12 and 24 h. The cells were then lysed by
suspending the pellet in Radio-immunoprecipitation assay (RIPA; Cell Signaling Technologies, Danvers,
Massachusetts) buffer supplemented with phenylmethylsulfonyl fluoride (PMSF; Sigma Aldrich, St,
MO, USA) at a concentration of 400 µL/107 cells. The protein was quantified by the bicinchoninic acid
(BCA, Cell Signaling Technologies, Danvers, MA, USA) assay following the manufacturer’s protocol.
Lysates (50 µg of protein) were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Proteins were then transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and
incubated with appropriate antibodies.
All primary and secondary antibodies were purchased from Cell Signaling Technologies and
were sourced from rabbit. Secondary antibody was anti-rabbit horseradish peroxidase (HRP)-linked.
The membrane was washed, then incubated with SignalFire reagent for 2 min and imaged using a
BioRad ChemiDoc MP Imaging system. If a membrane was re-probed for a different protein, the
membrane was stripped using Restore western blot stripping buffer (Thermo Scientific, Waltham, MA,
USA).
4.10. Tubulin Polymerization Assay
Tubulin polymerization was assessed using the Tubulin Polymerization Assay Kit
(Cytoskeleton, Denver, CO, USA) as per the manufacturer’s instructions. 7-epi-clusianone was
diluted in DMSO at 20 mM before being diluted to a 10× solution in General Tubulin Buffer. Paclitaxel
was used as the positive control. Absorbance correlating to the extent of polymerization was recorded
every minute for a total of one hour. Each experimental group was repeated in triplicate.
4.11. DiscoverX Kinase Panel
7-epi-clusianone was submitted to the DiscoverX KINOMEscan scanTK panel to determine its
ability to directly inhibit the function of 135 tyrosine kinases. The assay is an active site-directed
competition assay, which does not require the use of ATP to assess kinase function. One concentration
of 7-epi-clusianone (20 µM) was tested in the panel, and the results were reported as the percent of
remaining function for each kinase upon treatment with 7-epi-clusianone.
4.12. Macrophage Cytotoxicity Assay
Macrophage viability in response to 7-epi-clusianone treatment was assessed using CellTitter 96
Aqueous Non-Radioactive Cell Proliferation assay (Promega, Madison, WI, USA). THP-1 cells were
seeded into 96-well tissue culture plates (100,000 cells/well) and differentiated to THP-1 M0 macrophages.
After cell differentiation, the cells were exposed to various concentrations of 7-epi-clusianone for 72
h. Then, the cells were washed with PBS, and culture media supplemented 20% MTS solution
(Promega, Madison, WI, USA) was added to the cells. The cells were incubated for 2 h, and the
absorbance at 490 nm was measured using a Spectramax 190 microplate reader.
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4.13. Enzyme-Linked Immunosorbent Assay (ELISA)
THP-1 cells were differentiated to THP-1 M0 macrophages in a 24-well plate (300,000 cells/well)
and treated with 7-epi-clusianone for 72 h. The concentrations of tumor necrosis factor alpha (TNFα)
and interleukin-6 (IL-6) in the THP-1 M0 macrophages media were evaluated using human IL-6 and
TNFα tetramethylbenzidine (TMB) enzyme-linked immunosorbent assay (ELISA) development kits
(Peprotech, Rocky Hill, New Jersey) according to the manufacturer’s protocol. Colorimetric changes
were measured using a SpectraMax 190 microplate spectrophotometer at 450 nm with wavelength
correction set at 620 nm. Standard curves for each cytokine were run in parallel to convert the
absorbance to concentration in each group.
4.14. RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (rt-PCR)
We assessed the expression of pro-inflammatory genes (IL-6 and TNFα) expressed by THP-1 M0
macrophages in the presence or absence (control) of 7-epi-clusianone using rt-PCR. M1 macrophages
were used as a positive control to assess M0 macrophage polarization. Total RNA was isolated using the
Gene Jet RNA Purification kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s
instructions. The RNA was prepared as a template for complementary deoxyribonucleic acid (cDNA)
synthesis using the iScript cDNA Synthesis kit (Bio-Rad, Hercules, California). Quantitative rt-PCR
analysis was performed with the synthesized cDNA and SYBR Green PCR Supermix (Bio-Rad,
Hercules, CA, USA). Gene expression was normalized to the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and the control group, non-treated THP-1 M0 macrophages
(2−∆∆C ). Gene expression values were calculated by using the mean cycle threshold (CT) values of the
samples. All primers (Table S3) were synthetized by Integrated DNA Technologies (Integrated DNA
Technologies, Coralville, IA, USA).
4.15. Statistical Analysis
Statistical analyses were performed with GraphPad Prism 7.03 (GraphPad, La Jolla, CA, USA),
using multiple t-test followed by the Holm-Sidak method. Data represent the means of the indicated
number of independent experiments. Error bars indicate the standard error of the mean or the standard
deviation. p < 0.05 was considered to be significant.
Supplementary Materials: The following are available online, Figure S1: The A) 1 H-NMR spectrum, B) 13 C-NMR
spectrum, C) H-H COSY spectrum, D) HSQC spectrum, and E) HMBC spectrum of 7-epi-clusianone in DMSO-d6,
Figure S2: Time of flight mass spectrum determination of 7-epi-clusianone, Figure S3: Waterfall plot of the A)
GI50, B) TGI, and C) LC50 of 7-epi-clusianone for 60 cell lines as determined by the NCI-60 five dose screening
assay, Figure S4: The effect 7-epi-clusianone on A) the viability of THP-1 macrophages, and B) the percent wound
closure, Figure S5: Western blot analysis for the expression of Caspase 3 (A), Caspase 9 (B), Caspase 7 (C), Caspase
8 (D), PARP (E), and GAPDH (F). Table S1: Percent growth of the 60 cell lines examined in the NCI-60 five dose
screening method, Table S2: Inhibition of 135 tyrosine kinases treated with 7-epi-clusianone determine using the
DiscoverX scanTK kinase panel, and Table S3: Primers used for quantitative real-time polymerase chain reaction.
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